The Technical Analyst
Surface Oncology Inc [SURF]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Surface Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.93% $1.070
America/New_York / 7 sep 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 65.08 mill |
| EPS: | -1.560 |
| P/E: | -0.686 |
| Earnings Date: | Oct 30, 2023 |
| SharesOutstanding: | 60.82 mill |
| Avg Daily Volume: | 0.798 mill |
| RATING 2023-09-12 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.686 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.686 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.013 - 1.127 ( +/- 5.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
| 2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
| 2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
| 2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
| 2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
| INSIDER POWER |
|---|
| -73.04 |
| Last 94 transactions |
| Buy: 4 462 585 | Sell: 5 534 482 |
Forecast:
01:40 - $1.083
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.070 (-0.93% ) |
| Volume | 1.462 mill |
| Avg. Vol. | 0.798 mill |
| % of Avg. Vol | 183.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SURF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SURF
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2023-08-31 16:01:00 - Press Release
Surface Oncology Announces Iss And Glass Lewis Both Recommend Stockholders Vote “for” The Proposed Merger With Coherus Biosciences
Urges stockholders to vote promptly to ensure their shares are represented at the september 7th special meeting urges stockholders to vote promptly to ensure their shares are represented at the september 7th special meeting
2023-08-07 16:09:00 - Press Release
Surface Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Surface Oncology, Inc. - Surf
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of surface oncology, inc. (nasdaqgm: surf) to coherus biosciences, inc. (nasdaqgm: chrs). under the terms of the proposed transaction, coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of surface stock. surface shareholders will also receive certain co.
2023-08-02 07:00:00 - Press Release
Surface Oncology Reports Financial Results And Corporate Highlights For Second Quarter 2023
Cambridge, mass., aug. 02, 2023 (globe newswire) -- surface oncology (nasdaq: surf), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023.
2023-06-21 11:22:00 - Press Release
Surface Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Surface Oncology, Inc. - Surf
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of surface oncology, inc. (nasdaqgm: surf) to coherus biosciences, inc. (nasdaqgm: chrs). under the terms of the proposed transaction, coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of surface stock. surface shareholders will also receive certain co.
2022-11-07 08:00:00 - Press Release
Surface Oncology To Present Non-clinical Data For Srf388 And Srf114 At The Society For Immunotherapy Of Cancer 2022 Annual Meeting
Data further support srf388 and srf114 clinical development programs data further support srf388 and srf114 clinical development programs
Latest News
2023-06-20 13:09:06 - PennyStocks
Best Penny Stocks To Buy This Week? 3 To Watch Right Now
This will likely be another active week for traders. Whether you're trading penny stocks or higher priced shares of companies like Tesla (NASDAQ: TSLA) and Apple (NASDAQ: AAPL), chances are you're paying attention to stock market news headlines.
2023-06-16 11:01:17 - Proactive Investors
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The stock-for-stock transaction is valued at up to $65 million, approximately a three-fold premium over Surface's anticipated net cash of $20 million to $25 million at closing, the two companies said in a statement.
2023-06-16 07:51:00 - Market Watch
Surface Oncology stock rallies on all-stock acquisition by Coherus
Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSciences Inc. CHRS, +0.56% in a stock-for-stock deal valued at up to $65 million. Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock for a total value equal to the sum of $40 million.
2022-11-07 08:00:00 - GlobeNewsWire
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs
2022-09-14 07:30:00 - GlobeNewsWire
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -
2022-09-07 16:30:00 - GlobeNewsWire
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.
2022-05-26 17:00:00 - GlobeNewsWire
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –
2022-05-25 08:50:19 - Seeking Alpha
Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either.
2022-05-17 16:30:00 - GlobeNewsWire
Surface Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:
2022-04-27 16:15:00 - GlobeNewsWire
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.